Global Information
회사소개 | 문의 | 비교리스트

세계의 PDX(Patient Derived Xenograft) 모델 시장

Patient Derived Xenograft/PDX Models

리서치사 Global Industry Analysts, Inc.
발행일 2021년 04월 상품코드 913474
페이지 정보 영문 164 Pages 배송안내 1-2일 (영업일 기준)
가격
US $ 4,950 ₩ 6,436,000 PDF (Single User License)
US $ 14,850 ₩ 19,310,000 PDF (Global License to Company and its Fully-owned Subsidiaries)


세계의 PDX(Patient Derived Xenograft) 모델 시장 Patient Derived Xenograft/PDX Models
발행일 : 2021년 04월 페이지 정보 : 영문 164 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 PDX(Patient Derived Xenograft) 모델 시장의 개요, 동향·발전에 대한 영향요인 분석, 경쟁사와 시장 점유율, 세계 및 지역·주요 국가별 시장 규모의 추이와 예측, 주요 기업의 개요 등을 정리하여 전해드립니다.

제1장 조사 방법

제2장 개요

  • 시장 개요
    • 세계 시장의 기업 점유율
    • 세계 PDX(Patient Derived Xenograft) 모델 시장의 기업 점유율 시나리오
  • 주요 기업
  • 시장 동향과 발전 요인
  • 세계 시장 전망

제3장 시장 분석

  • 지역별 시장 분석
    • 미국
    • 캐나다
    • 일본
    • 중국
    • 유럽
    • 프랑스
    • 독일
    • 이탈리아
    • 영국
    • 기타 유럽
    • 아시아태평양
    • 기타 지역

제4장 경쟁사

  • CHAMPIONS ONCOLOGY
  • CHARLES RIVER LABORATORIES INTERNATIONAL
  • CROWN BIOSCIENCE
  • EPO BERLIN-BUCH GMBH
  • HERA BIOLABS
  • ONCODESIGN
  • PHARMATEST SERVICES LTD.
  • THE JACKSON LABORATORY
  • UROLEAD SAS
  • WUXI APPTEC
  • XENTECH

제5장 조사 자료

KSA 19.12.04

Abstract:

Global Patient Derived Xenograft/PDX Models Market to Reach $294.7 Million by 2027

Amid the COVID-19 crisis, the global market for Patient Derived Xenograft/PDX Models estimated at US$102.7 Million in the year 2020, is projected to reach a revised size of US$294.7 Million by 2027, growing at aCAGR of 16.3% over the period 2020-2027. Mouse, one of the segments analyzed in the report, is projected to record 15.3% CAGR and reach US$197.3 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Rat segment is readjusted to a revised 18.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $30.4 Million, While China is Forecast to Grow at 15.7% CAGR

The Patient Derived Xenograft/PDX Models market in the U.S. is estimated at US$30.4 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$51.2 Million by the year 2027 trailing a CAGR of 15.7% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 14.5% and 14% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 11.9% CAGR.

Select Competitors (Total 38 Featured) -

  • Champions Oncology, Inc.
  • Charles River Laboratories International, Inc.
  • Crown Bioscience, Inc.
  • Epo Berlin-Buch GmbH
  • Hera BioLabs
  • Oncodesign
  • Pharmatest Services Ltd.
  • The Jackson Laboratory
  • Urolead SAS
  • WuXi AppTec
  • Xentech

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Patient Derived Xenograft/PDX Models by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
    • TABLE 2: World 7-Year Perspective for Patient Derived Xenograft/PDX Models by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
    • TABLE 3: World Current & Future Analysis for Mouse by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
    • TABLE 4: World 7-Year Perspective for Mouse by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 5: World Current & Future Analysis for Rat by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
    • TABLE 6: World 7-Year Perspective for Rat by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Pre-Clinical Drug Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
    • TABLE 8: World 7-Year Perspective for Pre-Clinical Drug Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 9: World Current & Future Analysis for Basic Cancer Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
    • TABLE 10: World 7-Year Perspective for Basic Cancer Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 11: World Current & Future Analysis for Pharma & Biotech by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
    • TABLE 12: World 7-Year Perspective for Pharma & Biotech by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 13: World Current & Future Analysis for CRO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
    • TABLE 14: World 7-Year Perspective for CRO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 15: USA Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 16: USA 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
    • TABLE 17: USA Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 18: USA 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
    • TABLE 19: USA Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 20: USA 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
  • CANADA
    • TABLE 21: Canada Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 22: Canada 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
    • TABLE 23: Canada Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 24: Canada 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
    • TABLE 25: Canada Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 26: Canada 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
  • JAPAN
    • TABLE 27: Japan Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 28: Japan 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
    • TABLE 29: Japan Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 30: Japan 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
    • TABLE 31: Japan Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 32: Japan 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
  • CHINA
    • TABLE 33: China Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 34: China 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
    • TABLE 35: China Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 36: China 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
    • TABLE 37: China Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 38: China 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
  • EUROPE
    • TABLE 39: Europe Current & Future Analysis for Patient Derived Xenograft/PDX Models by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR
    • TABLE 40: Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
    • TABLE 41: Europe Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 42: Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
    • TABLE 43: Europe Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
    • TABLE 45: Europe Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 46: Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
  • FRANCE
    • TABLE 47: France Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 48: France 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
    • TABLE 49: France Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 50: France 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
    • TABLE 51: France Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 52: France 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
  • GERMANY
    • TABLE 53: Germany Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 54: Germany 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
    • TABLE 55: Germany Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Germany 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
    • TABLE 57: Germany Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 58: Germany 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
  • ITALY
    • TABLE 59: Italy Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 60: Italy 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
    • TABLE 61: Italy Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Italy 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
    • TABLE 63: Italy Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 64: Italy 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
  • UNITED KINGDOM
    • TABLE 65: UK Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 66: UK 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
    • TABLE 67: UK Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 68: UK 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
    • TABLE 69: UK Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 70: UK 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
  • REST OF EUROPE
    • TABLE 71: Rest of Europe Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 72: Rest of Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
    • TABLE 73: Rest of Europe Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 74: Rest of Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
    • TABLE 75: Rest of Europe Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 76: Rest of Europe 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 77: Asia-Pacific Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 78: Asia-Pacific 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
    • TABLE 79: Asia-Pacific Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Asia-Pacific 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
    • TABLE 81: Asia-Pacific Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 82: Asia-Pacific 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027
  • REST OF WORLD
    • TABLE 83: Rest of World Current & Future Analysis for Patient Derived Xenograft/PDX Models by Type - Mouse and Rat - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 84: Rest of World 7-Year Perspective for Patient Derived Xenograft/PDX Models by Type - Percentage Breakdown of Value Sales for Mouse and Rat for the Years 2020 & 2027
    • TABLE 85: Rest of World Current & Future Analysis for Patient Derived Xenograft/PDX Models by Application - Pre-Clinical Drug Development and Basic Cancer Research - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Rest of World 7-Year Perspective for Patient Derived Xenograft/PDX Models by Application - Percentage Breakdown of Value Sales for Pre-Clinical Drug Development and Basic Cancer Research for the Years 2020 & 2027
    • TABLE 87: Rest of World Current & Future Analysis for Patient Derived Xenograft/PDX Models by End-Use - Pharma & Biotech and CRO - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR
    • TABLE 88: Rest of World 7-Year Perspective for Patient Derived Xenograft/PDX Models by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech and CRO for the Years 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 38
Back to Top
전화 문의
F A Q